We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+64.77%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.62B
AUM Growth
+$549M
Cap. Flow
+$182M
Cap. Flow %
11.25%
Top 10 Hldgs %
48.03%
Holding
65
New
8
Increased
19
Reduced
26
Closed
8

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$64.8M
2
RPTX
Repare Therapeutics
RPTX
+$62.4M
3
RCUS icon
Arcus Biosciences
RCUS
+$49.8M
4
XOMA
Xoma
XOMA
+$27.5M
5
MRUS
Merus
MRUS
+$22.4M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$46.4M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$29M
3
RVMD icon
Revolution Medicines
RVMD
+$18.9M
4
SWTX
SpringWorks Therapeutics
SWTX
+$17.1M
5
CALA
Calithera Biosciences, Inc
CALA
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$96M 5.92%
2,286,891
-480,739
-17% -$17.1M
PRNB
2
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$88.8M 5.47%
1,484,674
-98,921
-6% -$6.11M
ARGX icon
3
argenx
ARGX
$53.9B
$87.8M 5.42%
390,000
+365,000
+1,460% +$64.8M
IONS icon
4
Ionis Pharmaceuticals
IONS
$8.61B
$83.9M 5.17%
1,422,842
-521,675
-27% -$29M
MRUS
5
DELISTED
Merus
MRUS
$81.9M 5.05%
5,090,571
+1,545,917
+44% +$22.4M
XOMA
6
DELISTED
Xoma
XOMA
$79.6M 4.91%
4,026,157
+1,252,772
+45% +$27.5M
ACIU icon
7
AC Immune
ACIU
$226M
$76.2M 4.7%
11,318,758
-23,747
-0.2% -$173K
XNCR icon
8
Xencor
XNCR
$1.53B
$67M 4.13%
2,068,098
+378,798
+22% +$11.6M
RPTX
9
DELISTED
Repare Therapeutics
RPTX
$60.3M 3.72%
+1,944,546
New +$62.4M
REPL icon
10
Replimune Group
REPL
$908M
$57.5M 3.55%
2,315,053
+339,844
+17% +$6.01M
FPRX
11
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$48.7M 3%
7,988,053
+205,052
+3% +$845K
RCUS icon
12
Arcus Biosciences
RCUS
$3.5B
$46.6M 2.87%
1,882,722
+1,844,148
+4,781% +$49.8M
IDYA icon
13
IDEAYA Biosciences
IDYA
$3.46B
$45.9M 2.83%
3,226,769
+1,941,940
+151% +$15.3M
KURA icon
14
Kura Oncology
KURA
$805M
$45.2M 2.79%
2,775,882
+341,186
+14% +$4.92M
XENE icon
15
Xenon Pharmaceuticals
XENE
$6.13B
$44.1M 2.72%
3,516,851
+842,513
+32% +$10.7M
PTGX icon
16
Protagonist Therapeutics
PTGX
$8.7B
$41.8M 2.58%
2,367,288
+1,674,858
+242% +$21M
CALA
17
DELISTED
Calithera Biosciences, Inc
CALA
$37.4M 2.31%
354,532
-123,450
-26% -$14.7M
SNDX icon
18
Syndax Pharmaceuticals
SNDX
$1.69B
$36.6M 2.26%
2,470,678
+330,894
+15% +$5.04M
CLDX icon
19
Celldex Therapeutics
CLDX
$2.96B
$35.6M 2.2%
+2,740,000
New +$12.1M
MTEM
20
DELISTED
Molecular Templates, Inc.
MTEM
$29.6M 1.83%
143,270
-46,748
-25% -$10.9M
ANAB icon
21
AnaptysBio
ANAB
$1.57B
$28.9M 1.78%
1,294,401
-395,836
-23% -$7.24M
CBIO
22
Crescent Biopharma
CBIO
$533M
$27.2M 1.68%
72,443
-1,175
-2% -$333K
IMVT icon
23
Immunovant
IMVT
$7.92B
$26.5M 1.63%
1,088,479
+88,483
+9% +$1.9M
CTMX icon
24
CytomX Therapeutics
CTMX
$686M
$26M 1.6%
3,115,537
-806,436
-21% -$7.49M
RVMD icon
25
Revolution Medicines
RVMD
$39.9B
$25.2M 1.55%
798,286
-599,784
-43% -$18.9M
1
2 3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2020 Portfolio in Review

As of Q2 2020, BVF Inc held 65 positions worth $1.62B, up 51% from $1.07B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

BVF Inc deployed $182M of net new capital in Q2 2020, opening 8 new positions and adding to 19 existing holdings. Its largest new stake was Repare Therapeutics: 1,944,546 shares worth $60.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $29M trimmed.

  • BVF Inc's largest Q2 2020 buy was Repare Therapeutics: 1,944,546 shares worth $60.3M.
  • BVF Inc added most to argenx in Q2 2020, an estimated $64.8M increase.
  • BVF Inc's biggest Q2 2020 reduction was Ionis Pharmaceuticals, cutting an estimated $29M.
  • BVF Inc fully exited Cytokinetics in Q2 2020, selling an estimated $46.4M.
  • BVF Inc's ten largest holdings make up 48% of its $1.62B portfolio in Q2 2020.
  • BVF Inc opened 8 new positions and closed 8 in Q2 2020.
  • BVF Inc's portfolio value rose 51% quarter-over-quarter to $1.62B.

Based on BVF Inc's 13F filing for Q2 2020, filed 14 Aug 2020.